XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Note 20 - Concentrations
3 Months Ended
Mar. 31, 2024
Notes to Financial Statements  
Concentration Risk Disclosure [Text Block]

Note 20. Concentrations

 

e-Commerce operations concentrations:

 

Customers:

 

Sales to customers through Amazon accounted for 39.9% and 57.2% of the Company’s revenues during the three months ended March 31, 2024 and 2023, respectively. No other customer accounted for 10% or more of the Company’s revenues for either period.

 

Suppliers:

 

The following table sets forth information as to each supplier that accounted for 10% or more of the Company’s purchases for the three months ended March 31, 2024 and 2023 (in thousands, unaudited).

 

  

For the Three Months Ended March 31, 2024

      

For the Three Months Ended March 31, 2023

     
                 

Globalstar Europe

 $213   10.2% $-   -%

Garmin

 $301   14.3% $594   20.9%

Iridium Satellite

 $270   27.2% $-   -%

 

Geographic:

 

The following table sets forth revenue as to each geographic location, for the  (in thousands, unaudited):

 

  

For the Three Months Ended March 31, 2024

      

For the Three Months Ended March 31, 2023

     
                 

Europe

 $1,430   49.9% $2,063   71.7%

North America

  523   18.3%  586   20.4%

South America

  23   0.8%  9   0.3%

Asia and Pacific

  413   14.4%  159   5.5%

Africa

  476   16.6%  59   2.1%
  $2,865   100% $2,876   100%

 

Healthcare operations concentrations:

 

Suppliers:

 

        Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were 98% of total vendor purchases for the three months ended March 31, 2024

 

Customers:

 

 Progressive Care s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not reimburse Progressive Care.

 

Progressive Care derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three most significant PBMs were as follows:

 

     
  

Three Months Ended March 31,

 
  

2024

 

A

  33%

B

  21%

C

  16%